Open AccessEmbolization of Chest Neoplasms: The Next Frontier in Interventional Oncology?
Author(s) -
Jonathan M. Lorenz,
Rakesh Navuluri
Publication year - 2019
Publication title -
seminars in interventional radiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.35
H-Index - 40
eISSN - 1098-8963
pISSN - 0739-9529
DOI - 10.1055/s-0039-1692658
Subject(s) - medicine , embolization , radiology , transarterial embolization , interventional radiology , lung , neoplastic disease , refractory (planetary science) , physics , astrobiology
The management of chest tumors and their sequelae has been an uncommon indication for transarterial embolization (TAE). More recently, vascular embolization has been increasingly performed for this indication. The most common reported indication for embolization of neoplastic disease in the chest is the control of bleeding resulting either from iatrogenic causes or from tumor invasion into a bronchus or vessel. A natural extension of the application of TAE to neoplasm-related hemoptysis is its burgeoning indication as a possible primary treatment for benign chest tumors, primary lung neoplasms, and metastatic disease in patients that are refractory to systemic therapies and have limited or no surgical options. The goals for this indication are tumor regression and management of bulk-related symptoms. In addition to bland TAE for this indication, authors have reported very initial results applying transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) to chest neoplasms with promising results that support feasibility and safety. This article is an up-to-date review of the management of chest tumors with embolization and its variants.